Questions to Ask Your Urologist and Oncologist Before Prostate Cancer Treatment

The folder sits on the kitchen table for three days before anyone opens it. Inside: a pathology report with a Gleason score, a PSA number that means nothing yet, and an appointment card with two names on it, a urologist and a radiation oncologist. The man it belongs to has told his brother, but not his colleagues. He has already searched, at two in the morning, for the questions to ask your urologist about prostate cancer, and found lists that all look the same.

What those lists rarely say is that prostate cancer is one of the few cancers where the first decision is sometimes to treat nothing at all, at least for now. That makes the conversation with your care team unusually consequential. The same diagnosis can lead one person to surgery, another to radiation, and a third to a schedule of blood tests and scans.

This guide is built around that reality. It explains what each question is really asking, what the evidence can and cannot tell you, and where your own priorities belong in the answer.

Why the questions to ask your urologist about prostate cancer matter so much

A prostate cancer consultation is different from most first cancer appointments. For many people, no one is racing the clock. The National Cancer Institute notes that many prostate cancers grow slowly and may never cause symptoms or shorten life, while others grow quickly and spread. Telling those two situations apart, and matching the treatment to the risk, is the entire job of the first few conversations.

That is why the questions you bring change the outcome of the visit. A person who asks only “what would you do?” usually gets a recommendation shaped by the specialty in the room. Urologists are surgeons by training; radiation oncologists treat with beams and implants. Both are acting in good faith, and both national guidance bodies, including the NHS, advise that people with localized disease should hear about surgery, radiation and active surveillance before choosing. Asking each specialist to describe the option they do not provide is a fair and useful test.

Three things are worth settling early:

• Your risk group, which combines grade, PSA and stage into a single category that drives most guideline recommendations.
• Whether your cancer is one that guidelines consider suitable for monitoring rather than immediate treatment.
• What trade-offs you personally care about most: continence, erections, avoiding surgery, avoiding daily hospital visits, or simply certainty.

Write the questions down. Take someone with you, or ask whether you can record the conversation. The Mayo Clinic’s own preparation advice for this appointment is almost identical: list your questions in order of importance, because time runs out before questions do.

What actually happens between diagnosis and a treatment decision

Most people picture a diagnosis followed immediately by a plan. In practice, there is usually a staging phase in between, and knowing its steps helps you ask better questions at each one.

The biopsy is only the beginning. A pathologist assigns a Gleason score, a grading system in which the two most common patterns of cancer cells are each scored and added together; these are now grouped into grade groups 1 through 5, with 1 the least aggressive, as described in the National Cancer Institute’s treatment summary. Your PSA, a protein made by the prostate and measured in blood, is added to that. So is the clinical stage, an estimate of how far the tumor extends, based on examination, MRI and sometimes bone or PET scans if the grade or PSA suggests spread might be possible.

Those three pieces produce a risk category: very low, low, intermediate or high risk for localized disease, with further subdivisions in some guidelines. Almost every recommendation you hear afterward flows from that label, which is why it belongs at the top of your question list.

Many cancer services then review the case in a multidisciplinary meeting, where urologists, oncologists, radiologists and pathologists look at the same scans and slides together. The NHS describes this as standard practice. You can ask whether your case was discussed that way and what the group concluded.

Only then does the treatment conversation begin. If you feel rushed before staging is complete, it is reasonable to say so. Ask what information is still missing and how the plan might change once it arrives.

Questions about your grade, stage and risk group

Ask for the numbers, and then ask what they mean together. A grade group 1 cancer with a low PSA and a small tumor felt on nothing but MRI is a very different disease from a grade group 4 cancer with a rising PSA, even though both are called prostate cancer.

Useful questions here include:

• What is my Gleason score and grade group, and how many biopsy cores contained cancer?
• What is my PSA, and does my PSA density, which is PSA divided by prostate volume, change how you read it?
• What did the MRI show, and did the biopsy target the area seen on the scan?
• What is my clinical stage, and do I need any further imaging before we decide?
• Which risk group am I in, and which guideline are you using to place me there?

That last question matters more than it sounds. Guidelines from different organizations draw the lines in slightly different places, and the treatments they consider reasonable widen or narrow accordingly.

Ask, too, whether a second pathology opinion is available. Gleason grading involves judgment, and the Cleveland Clinic notes that a second review of biopsy slides is a common request. A change from grade group 1 to 2, or the reverse, can move someone across the boundary between surveillance and treatment.

If genetic or genomic testing is mentioned, ask two things: what decision the result would change, and what happens if the result is uncertain. Tests that cannot alter your plan add anxiety without adding value, and a good clinician will say so plainly.

What are the characteristics of very low-risk prostate cancer?

“Very low risk” is a specific category, not a reassurance. Guideline definitions vary in detail, but they cluster around the same features described in the National Cancer Institute’s treatment summary and by the Cleveland Clinic: grade group 1 disease, a PSA below the threshold the guideline sets for low risk, a tumor too small to feel on examination and found only through biopsy, cancer in only a small number of biopsy cores with only a small proportion of each core involved, and a low PSA density.

Why does this category exist? Because grade group 1 cancers, on the current evidence summarized by these sources, very rarely spread. Treating them carries the usual risks of surgery or radiation without a clear benefit for most people, at least in the near term. This is the group for whom active surveillance is most consistently recommended.

Questions that fit this situation:

• Do I meet every criterion for very low risk, or only some of them?
• Was my MRI clear, and was the biopsy systematic, targeted or both?
• How confident are you that a higher-grade area was not missed?
• What would move me out of this category during follow-up?

A caution belongs here. Being placed in the very low-risk group depends on the biopsy having sampled the prostate well. The reason surveillance protocols include repeat MRI and biopsy is precisely to catch cancers that were undergraded the first time. Ask how your team handles that possibility rather than assuming the first report is the last word.

Who is usually offered active surveillance, and who is asked to wait

Active surveillance is close monitoring of a cancer that has not been treated, with the intention of treating it if it shows signs of progressing. It is not the same as doing nothing, and it is not the same as watchful waiting, a less intensive approach used when someone is unlikely to benefit from treatment because of age or other illness.

The NHS describes a typical surveillance schedule as regular PSA blood tests every few months, alongside repeat MRI scans and, at intervals, repeat biopsies. The exact rhythm varies between services, so ask for yours in writing.

Who is usually offered it? People with very low-risk and most low-risk localized cancers, and, in some guidelines, selected people with favorable intermediate-risk disease after a careful discussion. Who is usually steered toward treatment instead? Those with higher grade groups, higher PSA, or imaging suggesting the tumor is larger or reaching the edge of the gland. Individual health, life expectancy and personal preference shape the decision in both directions.

Questions to ask:

• Am I a candidate for active surveillance under the guideline you use?
• What findings would prompt you to recommend treatment, and how quickly would that happen?
• Would treating later carry the same options and expected outcomes as treating now?
• How will you help me manage the uncertainty of living with an untreated cancer?

That last point is not soft. Some people find surveillance intolerable and choose treatment for peace of mind; others find the idea of avoidable side effects far worse. Neither is wrong, and your team should be willing to say that out loud.

Prostate cancer treatment options at a glance

The main approaches for localized and locally advanced disease are summarized below, drawing on descriptions from the National Cancer Institute, the NHS and the Mayo Clinic. The table is a map for your conversation, not a ranking. Which option is reasonable for you depends on your risk group, health and priorities.

Approach	What it involves	Usually discussed for	Side effects to ask about
Active surveillance	Regular PSA tests, MRI and periodic biopsy; treatment only if the cancer progresses	Very low and low risk; some favorable intermediate risk	Anxiety, repeat biopsy discomfort, possibility of later treatment
Radical prostatectomy	Surgical removal of the prostate and seminal vesicles, open or robot-assisted, sometimes with lymph nodes	Localized and some locally advanced disease	Urinary leakage, erectile dysfunction, loss of ejaculation, surgical risks
External beam radiotherapy	Focused radiation delivered in daily outpatient sessions across several weeks	Localized and locally advanced disease; often with hormone therapy at higher risk	Bowel changes, urinary urgency, erectile dysfunction developing over time, fatigue
Brachytherapy	Radioactive seeds or temporary sources placed directly in the prostate	Selected low and intermediate risk; sometimes combined with external beam	Urinary irritation, erectile dysfunction, less often bowel symptoms
Hormone therapy	Medicines that lower or block testosterone, which prostate cancer uses to grow	Alongside radiation at intermediate and high risk; advanced disease	Hot flashes, fatigue, bone thinning, weight and mood changes, metabolic effects

Two honest points. Head-to-head evidence comparing surgery and radiation for localized disease shows both are used with similar goals, and guidelines from the NHS and others present them as alternatives rather than a hierarchy. And the side-effect profiles differ in timing as much as type: surgical effects tend to appear immediately and improve, while radiation effects often emerge more slowly. Ask each specialist how they would explain the option they do not deliver.

Questions to ask a urologist about prostate surgery

Radical prostatectomy is the surgical removal of the whole prostate gland and the seminal vesicles, the small glands that produce part of the seminal fluid. It may be done through an open incision or with laparoscopic or robot-assisted techniques, and the Mayo Clinic notes that nearby lymph nodes are sometimes removed at the same time when spread is a concern.

Because the nerves controlling erections run along the outside of the prostate, and the urinary sphincter sits just below it, the two side effects people ask about most are erectile dysfunction and urinary leakage. Both are common early on and both can improve, but neither can be promised. A nerve-sparing approach, in which the surgeon attempts to preserve those nerve bundles, is only appropriate when the cancer is not close to them, which is a question for your specific scans.

Ask your urologist:

• Is nerve-sparing surgery realistic in my case, on one side or both?
• Will lymph nodes be removed, and how will the results change follow-up?
• What is the typical hospital stay and catheter duration in your service? The NHS describes a catheter for one to two weeks after surgery as usual.
• What pelvic floor preparation do you recommend before the operation?
• How will we measure whether the surgery achieved its aim, and what would a detectable PSA afterward mean?
• If the pathology after surgery shows higher-risk features, what happens next?

It is reasonable to ask a surgeon how many of these procedures they perform, but treat the answer as one input, not a verdict. A more revealing question is how they handle complications and who you call at night in the first two weeks.

Questions to ask an oncologist about prostate cancer radiation and hormone therapy

A radiation oncologist treats cancer with targeted radiation. External beam radiotherapy is delivered from outside the body in short outpatient sessions, typically daily across several weeks according to the NHS, with newer schedules compressing the course into fewer, larger sessions in suitable people. Brachytherapy places radioactive sources inside the prostate itself.

For intermediate and high-risk disease, radiation is often paired with hormone therapy, also called androgen deprivation therapy. These medicines lower testosterone or block its action; prostate cancer cells depend on that hormone to grow, so removing the signal slows them. The Mayo Clinic lists hot flashes, fatigue, loss of muscle and bone density, and changes in mood and metabolism among the recognized effects. The duration of hormone therapy alongside radiation is set by risk group and is a decision for the prescribing clinician.

Questions to ask your oncologist:

• Which radiation technique and schedule do you recommend, and why that one for my risk group?
• Would hormone therapy be added, for what purpose, and for how long a course?
• How do bowel and urinary side effects typically evolve over the months after treatment?
• What bone health and cardiovascular monitoring accompanies hormone therapy?
• What would a rising PSA after radiation mean, and what options would remain?

One point people are often surprised by: after radiation, the prostate stays in place, so PSA does not fall to zero and is interpreted differently than after surgery. Ask how your team defines a concerning rise so you are not alarmed by a number that is expected.

How often is prostate cancer aggressive, and how would I know if mine is?

People searching this question usually want a single percentage. The honest answer is that aggressiveness is a spectrum, and the tools used to place a cancer on it are exactly the ones already in your pathology report.

The CDC and the National Cancer Institute both describe most prostate cancers as slow-growing, with a smaller proportion behaving aggressively. Rather than quoting a number that depends heavily on how a population was screened, it is more useful to know the markers of aggressive behavior that guidelines rely on: grade group 4 or 5, a high or rapidly rising PSA, cancer in many biopsy cores, a tumor extending beyond the gland on MRI or examination, and any evidence of spread to lymph nodes or bone.

Ask directly:

• On my grade, PSA and stage, would you describe this cancer as indolent, intermediate or aggressive?
• What features in my report worry you, and which reassure you?
• Do I need a bone scan or PET imaging before we decide? The NHS notes these are used when higher grade or PSA raises the possibility of spread.
• Does my family history or any genetic result change your assessment?

The value of this framing is that it turns a frightening abstraction into a checklist your team can answer from your own results. A grade group 1 cancer confined to the gland is, by every mainstream definition, at the low end of that spectrum. A grade group 5 cancer with a high PSA is at the other, and the recommended treatments differ accordingly. Knowing where you sit is the foundation of every other question in this article.

What other cancers are linked to prostate cancer? Questions about family history

This question has two sides: inherited links that run in families, and links related to treatment.

On inheritance, the Mayo Clinic and the National Cancer Institute note that a family history of prostate cancer raises risk, and that inherited variants in genes such as BRCA1 and BRCA2, better known for breast and ovarian cancer, are also associated with prostate cancer, sometimes of a more aggressive type. Lynch syndrome, an inherited condition linked to bowel and other cancers, is another association described in the National Cancer Institute’s material. That is why a thorough consultation asks not only about fathers and brothers, but about mothers, sisters and daughters with breast, ovarian or pancreatic cancer.

Questions to bring:

• Given my family history, do you recommend genetic counseling or testing?
• If I carry a variant, does that change my treatment options or my follow-up?
• What should my children and siblings know, and who can advise them?

On treatment-related links, radiation to the pelvis is associated with a small long-term increase in the risk of other cancers in the treated area, a point the Mayo Clinic includes among the considerations for radiotherapy. Ask your oncologist what that means in absolute terms for someone of your age, because the same small risk weighs differently at fifty-five than at eighty.

Be prepared for the answer “we don’t know precisely.” For many of these associations, the evidence shows a connection without a firm number for an individual. A clinician who says that is being accurate, not evasive.

What the following days and weeks usually look like after prostate cancer treatment

Recovery timelines are typical ranges drawn from mainstream sources, never a promise. Your own team will give you the version that fits your health and your procedure.

After radical prostatectomy, the Mayo Clinic describes a hospital stay of about a day or two for most people, and the NHS describes a urinary catheter, a soft tube draining the bladder, staying in place for around one to two weeks. Urinary leakage is common when the catheter comes out and typically improves over subsequent weeks and months with pelvic floor exercises. Erections, where they return, tend to recover gradually over months rather than weeks. Heavy lifting and strenuous exercise are usually restricted for several weeks; ask for your surgeon’s specific limits.

After external beam radiation, the daily visits themselves are short, but the NHS notes that tiredness and bowel or urinary irritation often build toward the end of the course and settle in the weeks afterward. Some effects, particularly on erections and bowel habit, can appear months later, which is why follow-up continues well beyond the last session.

Hormone therapy effects emerge as testosterone falls, generally over the first weeks, and continue for as long as the treatment does.

Questions for this phase:

• When is my first PSA after treatment, and what result are you expecting?
• Who do I contact about a problem in the first two weeks, and how?
• Should I be referred to pelvic floor physiotherapy or a sexual health clinic?
• When can I drive, return to work and resume exercise?

Write down the answers. The early weeks are when small, fixable problems most often go unreported.

Can you have a normal life after prostate cancer? Life after prostate cancer treatment

Many people do return to work, travel, exercise and relationships, and the National Cancer Institute and NHS both frame prostate cancer as a condition that many live with or beyond for years. What “normal” looks like, though, depends on which side effects you experience and how well they are managed. It is fair to ask your team about that future in concrete terms rather than accepting a general reassurance.

Areas worth raising:

• Continence. Ask what proportion of people in your service need pads beyond the first months and what support exists if leakage persists, including physiotherapy and, later, procedures.
• Sexual function. Ask about the mechanisms available to help erections recover, how soon a rehabilitation approach might begin, and whether a referral to a specialist clinic is routine.
• Fatigue and mood. Hormone therapy in particular can affect energy, sleep and emotional wellbeing. Ask who monitors this.
• Bone and heart health. Ask what monitoring accompanies longer courses of hormone therapy, since the Mayo Clinic lists bone thinning and metabolic changes among its effects.
• Follow-up. Ask how often PSA is checked, for how many years, and who owns that schedule.

A frank conversation about sex and continence before treatment is not a distraction from the cancer. It is part of choosing between options that differ mainly in these effects. If a clinician seems uncomfortable, ask for a nurse specialist or a referral; most services have someone whose role is exactly this.

Life afterward is rarely identical to life before. For many people it is, with support, recognizably their own.

What people often get wrong about prostate cancer decisions

Some misunderstandings surface at nearly every first appointment. Correcting them early saves regret later.

“Faster is safer.” For low-risk disease, guidelines from the NHS and the National Cancer Institute explicitly endorse taking time to gather information and consider surveillance. Days or weeks spent deciding are not lost.

“Surveillance means giving up.” Active surveillance is a structured program with defined triggers for treatment. It is a positive choice made because the evidence supports it in the right people, not a concession.

“Surgery removes all doubt.” Removing the prostate does not guarantee the cancer is gone; PSA follow-up continues afterward for exactly that reason, and further treatment is sometimes recommended based on the post-operative pathology.

“Radiation is the gentle option.” Its side effects arrive on a different timetable, not a smaller one. Bowel and urinary symptoms can appear months later, and hormone therapy, when added, brings its own effects.

“A second opinion will offend my doctor.” The Cleveland Clinic and the Mayo Clinic both list seeking another view as a reasonable step, and most clinicians expect it for a decision this large.

“Diet or supplements can replace treatment.” No dietary approach or supplement has been shown to control diagnosed prostate cancer in place of guideline treatment. Eating well supports overall health during treatment, which is a different claim.

“PSA after treatment should be zero.” That expectation applies after surgery, not after radiation, where the gland remains and a low but detectable PSA is expected. Knowing which rule applies to you prevents needless alarm at the first follow-up blood test.

Questions to ask your care team: a compact list to bring

Print this, cross out what does not apply, and add your own at the bottom. Ask the same core questions of both specialists; where their answers differ, that difference is itself useful information.

About my cancer

• What are my grade group, PSA and stage, and which risk group do they place me in?
• Do I need any more tests before deciding?
• Was my case reviewed by a multidisciplinary team?

About my options

• Which of surveillance, surgery and radiation are reasonable for me, and which are not, and why?
• How would you describe the option you do not provide?
• If we treat later rather than now, what changes?

About side effects

• For each option, what are the likely effects on urination, bowel function and sex, and on what timeline?
• What support exists for each of those, and is referral routine?

About the process

• What does the first month after treatment look like, day by day?
• Who do I contact with a problem, including out of hours?
• How and how often will you check whether treatment worked?

About me

• Given my other health conditions and age, how do you weigh benefits against side effects?
• Should I see a genetic counselor?
• Is there a clinical trial appropriate for my situation?

Finish with one question that the National Cancer Institute suggests for any cancer visit: “Is there anything I haven’t asked that you think I should know?” It frequently produces the most useful answer of the day.

When to call your doctor

Most of the decisions in this article unfold over weeks, but some situations should not wait for the next scheduled appointment. Every treatment team provides a contact route for these, and using it is expected, not an imposition.

Contact your care team promptly, or seek urgent care, if you notice any of the following, whether you are on surveillance, recovering from treatment or between visits:

• A fever, chills or shaking after a biopsy, surgery or catheter removal, which can signal infection.
• Inability to pass urine, or a catheter that stops draining.
• Heavy or persistent blood in the urine or stool, or large clots.
• New, severe or worsening back, hip or bone pain, particularly with numbness, weakness or tingling in the legs, or new difficulty controlling the bladder or bowel. The NHS lists these among signs that need urgent assessment because they can indicate pressure on the spinal cord in someone with prostate cancer.
• A swollen, painful calf, or sudden breathlessness or chest pain after surgery, which can indicate a blood clot.
• Wound redness, opening or discharge.
• Persistent vomiting, or an inability to keep fluids down.
• Low mood that does not lift, or thoughts of self-harm, at any stage of treatment.

Outside emergencies, a rising PSA on a follow-up test is a reason for a conversation, not panic; your team will have told you in advance what kind of change they consider significant. Any new symptom you cannot explain is worth a phone call. The people who do best after a prostate cancer diagnosis are rarely those who tolerated the most quietly; they are the ones who told their team early and let the plan be adjusted.

Frequently asked questions

What are the most important questions to ask a urologist about prostate cancer?

Start with your grade group, PSA and stage, and the risk category they produce. Then ask whether active surveillance is reasonable for you, what surgery and radiation each involve, their typical side effects and recovery timelines, how success will be measured with PSA afterward, and who coordinates your follow-up. Asking each specialist to describe the option they do not provide is especially revealing.

What questions should I ask an oncologist about prostate cancer radiation?

Ask which radiation technique and schedule they recommend for your risk group and why, whether hormone therapy would be added and for how long a course, how bowel and urinary effects typically evolve over the following months, what monitoring accompanies hormone therapy for bone and heart health, and what a rising PSA after radiation would mean given that the prostate remains in place.

Can you have a normal life after prostate cancer?

Many people return to work, exercise, travel and relationships after treatment, and both the NHS and the National Cancer Institute describe prostate cancer as a condition many live beyond for years. How close life feels to normal depends largely on urinary, bowel and sexual side effects and how well they are supported, which is why those topics belong in the pre-treatment conversation.

How often is prostate cancer aggressive?

Most prostate cancers are slow-growing according to the CDC and National Cancer Institute, with a smaller proportion behaving aggressively. A precise percentage depends on how a population was screened, so it is more useful to ask about your own markers: grade group 4 or 5, a high or rising PSA, many positive biopsy cores, or imaging showing extension beyond the gland.

What are the characteristics of very low-risk prostate cancer?

Very low-risk disease generally means grade group 1 cancer, a PSA below the guideline’s low-risk threshold, a tumor found only on biopsy and not felt on examination, cancer in few biopsy cores with limited involvement of each, and a low PSA density. Definitions differ slightly between guidelines, so ask which criteria your team applied and whether you meet all of them.

What other cancers are linked to prostate cancer?

Inherited variants in BRCA1 and BRCA2, best known for breast and ovarian cancer, and the genes behind Lynch syndrome, linked to bowel and other cancers, are associated with prostate cancer according to the Mayo Clinic and National Cancer Institute. Pelvic radiation also carries a small long-term increase in risk of other cancers in the treated area, which your oncologist can put into perspective.

What prostate cancer treatment options should my doctor discuss with me?

For localized disease, guidelines expect a discussion of active surveillance, radical prostatectomy and radiotherapy, including brachytherapy where suitable, with hormone therapy added to radiation at intermediate and high risk. Watchful waiting may be raised for people unlikely to benefit from treatment. Which options are reasonable for you depends on your risk group, health and priorities, and the decision rests with you and your treating team.

Should I get a second opinion before prostate cancer treatment?

It is a reasonable and common step, and both the Mayo Clinic and the Cleveland Clinic list it among options after diagnosis. A second pathology review of biopsy slides can occasionally change the grade group, and a consultation with a specialist in the treatment you have not yet discussed helps ensure you have heard the full range of guideline options.

How long does recovery take after prostate cancer surgery?

The Mayo Clinic describes a hospital stay of about a day or two for most people, and the NHS describes a urinary catheter staying in for around one to two weeks. Leakage is common when it is removed and usually improves over following weeks and months; erectile recovery, where it occurs, is typically gradual over months. Your surgeon will give limits on lifting and exercise specific to you.

What does active surveillance for prostate cancer involve?

Active surveillance is close monitoring of an untreated cancer with the intention of treating it if it progresses. The NHS describes regular PSA blood tests every few months, alongside repeat MRI scans and periodic biopsies. It is offered mainly for very low and low-risk disease, differs from watchful waiting, and includes defined triggers that would prompt your team to recommend treatment.

References

• Prostate cancer – Treatment, NHS
• Treatment of Prostate Cancer, CDC
• Prostate Cancer, MedlinePlus
• Prostate Cancer, Cleveland Clinic

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.